Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.51 +5.14%

+$0.45 today

Market cap
$53.05M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.00M

Average 0.05M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$4.99M

FY 2025 · Annual

Investing Cash Flow

-$518,000.00

FY 2025 · Annual

Financing Cash Flow

$87.78M

FY 2025 · Annual

+200.6% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
Deferred Income Tax222K0000
Stock-Based Compensation4.96M8.42M7.38M6.43M6.94M
Change in Working Capital(11.8M)2M(1.66M)31.78M25.13M
Accounts Receivables0000(5M)
Inventory00000
Accounts Payables(2.82M)485K(2.06M)1.53M152K
Other Working Capital(8.99M)1.52M405K30.26M29.97M
Other Non-Cash Items173K224K160K3K(3.56M)
Operating Cash Flow(80.75M)(75.72M)(68.62M)(18.38M)(4.99M)
Capital Expenditures(1.1M)(1.87M)(486K)(36K)(518K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.1M)(1.87M)(486K)(36K)(518K)
Debt Repayment(110K)(85K)(6.75M)(3.38M)0
Common Stock Issued116.36M16K202K6.83M87.78M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(467K)0025.75M0
Financing Cash Flow260.67M(69K)(6.55M)29.2M87.78M
Effect of Forex Changes0(9K)(25K)00
Net Change in Cash178.82M(77.67M)(75.68M)10.78M82.27M
Free Cash Flow(81.85M)(77.59M)(69.11M)(18.41M)(5.51M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$35.0M
+ D&A$1.5M
+ Stock-Based Comp$6.9M
+ Deferred Tax$0
+ Working Capital$25.1M
- Other Non-Cash-$3.6M
= Operating Cash Flow-$5.0M
- Capex-$518.0K
= Free Cash Flow-$5.5M

Analysis

FY2025 free cash flow is -$5.5M. FCF conversion is 15.7% of net income. Operating cash flow was -$5.0M, with capex of -$518.0K. The largest bridge item is Working Capital at $25.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 12, 2026
S-8S-8 filingNov 10, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026

Does XLO generate free cash flow?

Xilio Therapeutics, Inc. (XLO) generated -$5.51M of free cash flow in fiscal 2025.

How much operating cash flow does XLO produce?

Operating cash flow was -$4.99M, before capital expenditures of $518,000.00.